We present a 77-year-old woman with wild-type ATTR cardiac amyloidosis (ATTR-CA) who presented with dyspnea, arrhythmia, and elevated NT-pro BNP. Initial imaging including cardiac MRI, PYP scintigraphy, PiB PET/CT and NaF PET/CT revealed cardiac abnormalities. Tafamidis treatment was initiated. After 14 months, symptomatic improvement and reduced NT-pro BNP were observed. Cardiac MRI and PYP scintigraphy showed no significant change and increased NaF accumulation, while PiB PET/CT showed decreased amyloid deposition, suggesting that it may be superior to NaF PET/CT in assessing the therapeutic effect of tafamidis in ATTR-CA.

中文翻译：

---

PiB 正电子发射断层扫描/计算机断层扫描用于 Tafamidis 治疗监测转甲状腺素蛋白心脏淀粉样变性患者的可行性

我们介绍了一名患有野生型 ATTR 心脏淀粉样变性 (ATTR-CA) 的 77 岁女性，她出现呼吸困难、心律失常和 NT-pro BNP 升高。初步影像学检查（包括心脏 MRI、PYP 闪烁扫描、PiB PET/CT 和 NaF PET/CT）显示心脏异常。开始Tafamidis治疗。14 个月后，观察到症状改善和 NT-pro BNP 减少。心脏MRI和PYP闪烁扫描未显示明显变化，NaF积累增加，而PiB PET/CT显示淀粉样蛋白沉积减少，表明在评估tafamidis对ATTR-CA的治疗效果方面可能优于NaF PET/CT。